Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment Meeting Abstract
| Authors: | Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; Alencar, A. J.; Lewis, D.; Patel, K.; Maddocks, K.; Wang, Y.; Munir, T.; Zelenetz, A. D.; Balbas, M.; Tsai, D. E.; Wang, C. |
| Abstract Title: | Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | tp53 mutation; mcl; pirtobrutinib; btk-inhibitor |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S459 |
| Language: | English |
| ACCESSION: | WOS:001062479600505 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01372-1 |
| Notes: | Meeting Abstract: MCL-155 -- Source: Wos |
